Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene
March 29, 2012 16:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 29, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Representation of PMS2 mutations in patients seeking genetic...
Myriad and Cephalon Enter Into Companion Diagnostic Agreement
March 28, 2012 16:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical...
Supreme Court of the United States Remands Gene Patenting Case
March 26, 2012 12:37 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the Supreme Court of the United States remanded the case of The Association for Molecular...
Prolaris(R) Test Awarded Best Poster Honor at 27th Annual EAU Congress in Paris, France
February 27, 2012 16:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved...
Myriad's Prolaris(R) Test Shown to Significantly Predict Prostate Cancer Outcome in Needle Biopsy Tissue
February 24, 2012 07:45 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the prognostic ability of the...
Myriad Genetics to Present at the Cowen and Company 32nd Annual Health Care Conference
February 22, 2012 16:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the...
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference
February 06, 2012 16:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Jim Evans, Chief Financial Officer, is scheduled to present at the Leerink Swann 2012 Global...
Myriad's Prolaris(R) Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy
February 02, 2012 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 2, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved...
Myriad Genetics Reports Second Quarter Fiscal Year 2012 Results
January 31, 2012 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 31, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter and six months ending December 31, 2011. Revenue for the...
Myriad Genetics Acquires Exclusive Rights to RAD51C Gene
January 18, 2012 16:10 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 18, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C...